Effects of Immulina TM Supplements with PASC Patients

Description

This is a multi-site study that will try to determine the effects of Immulina ™, a natural dietary supplement, on blood chemicals associated with inflammation that are often increased in patients with long COVID (also called PASC).

Conditions

Post Acute COVID-19 Syndrome

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a multi-site study that will try to determine the effects of Immulina ™, a natural dietary supplement, on blood chemicals associated with inflammation that are often increased in patients with long COVID (also called PASC).

Effect of Immulina Supplements on Inflammatory Biomarkers Correlated with Clinical Symptoms in Patients with Long COVID (PASC)

Effects of Immulina TM Supplements with PASC Patients

Condition
Post Acute COVID-19 Syndrome
Intervention / Treatment

-

Contacts and Locations

Honolulu

University of Hawaii, Honolulu, Hawaii, United States, 96813

Baton Rouge

Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States, 70808

New Orleans

Louisiana State University, New Orleans, Louisiana, United States, 70112

Portland

MaineHealth, Portland, Maine, United States, 04101

Jackson

University of Mississippi Medical Center, Jackson, Mississippi, United States, 39216

Omaha

University of Nebraska Medical Center, Omaha, Nebraska, United States, 68198

Oklahoma City

University of Oklahoma, Oklahoma City, Oklahoma, United States, 73104

Morgantown

West Virginia University, Morgantown, Virginia, United States, 26506

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Males and females, 18 to 99 years old
  • * If female of child bearing potential, using acceptable means of birth control or postmenopausal for at least two years
  • * Body temperature between 36.1°C and 37.7°C.
  • * Has completed the 4-week washout period (if applicable), i.e., has refrained from using internally-consumed dietary supplements prior to Study Day 1 and through the completion of the study
  • * A minimum of 2 hours fasting (except water) prior to all of the blood draws
  • * Willing and able (in the opinion of study staff) to comply with all study requirements, including swallowing size 4 capsules (approximately 0.5" long and 0.25" diameter) and having phlebotomy
  • * Good written and verbal English skills; able to follow instructions (in the investigator's opinion)
  • * Not participating in a clinical study, currently or within the last 30 days
  • * Signed informed consent
  • * Pregnant or lactating
  • * Digestive tract disorders or conditions, such as (but are not limited to): ulcers, ulcerative colitis, Crohn's disease, gastric bypass, colostomy, ischemic colitis, gastroesophageal reflux disease (GERD), irritable bowel disease (IBD), diverticulitis that would be expected to impact on the oral disposition of the Immulina dietary supplement
  • * Existence of any surgical and/or medical condition, significant disease or disorder, or any finding that may, in the judgment of the investigator, put the volunteer at risk or compromise study participation.
  • * Any blood-thinning or clotting concomitant medication (prescription anticoagulants)
  • * Donation or loss of 400 mL or more of blood within 8 weeks of Study Day 1 or unwilling to abstain from donation of blood during the study
  • * Known or suspected allergy or sensitivity to Immulina, cellulose
  • * History of drug or alcohol abuse within the last 12 months

Ages Eligible for Study

18 Years to 99 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Mississippi Medical Center,

Gailen D Marshall, Jr., MD, PhD, PRINCIPAL_INVESTIGATOR, University of Mississippi Medical Center

Study Record Dates

2025-12-31